Factori de risc pentru apariția sindromului hepatorenal la pacienții cu ciroză hepatică

September 2010
Romanian Journal of Medical Practice;2010, Vol. 5 Issue 3, p211
Academic Journal
Hepatorenal syndrome, a yet unsufficiently explored entity with an uncertain physiopathological mechanism, is characterized by functional renal failure in patients with hepatic failure, especially those with cirrhosis. In spite of thorough researches, any really efficient treatment besides hepatic transplant has been demonstrated yet. In patients with cirrhosis who exhibit hepatic hypotrophy, serum albumin under 3mg%, prothrombin level under 75%, viral etiology cirrhosis, Child C score affiliation, all necessary measures must be taken in order to prevent the development of this syndrome.


Related Articles

  • Molecular adsorbent recirculating system is ineffective in the management of type 1 hepatorenal syndrome in patients with cirrhosis with ascites who have failed vasoconstrictor treatment. Wong, Florence; Raina, Nilima; Richardson, Robert // Gut;Mar2010, Vol. 59 Issue 3, p381 

    Background The pathogenetic mechanism of hepatorenal syndrome (HRS) is paradoxical renal vasoconstriction consequent upon systemic and splanchnic arterial vasodilatation. Molecular adsorbent recirculating system (MARS) is a specialised form of dialysis that clears albumin-bound substances,...

  • DIAGNOSIS, PREVENTION AND TREATMENT OF HEPATORENAL SYNDROME IN CIRRHOSIS. Salerno, Francesco; Gerbes, Alexander; Ginès, Pere; Wong, Florence; Arroyo, Vicente // Gut;Sep2007, Vol. 56 Issue 9, p1310 

    Hepatorenal syndrome (HRS) is a serious complication of end-stage liver disease, occurring mainly in patients with advanced cirrhosis and ascites, who have marked circulatory dysfunction, as well as in patients with acute liver failure. In spite of its functional nature, HRS is associated with a...

  • The efficacy and safety of terlipressin and albumin in patients with type 1 hepatorenal syndrome: a multicenter, open-label, explorative study. Narahara, Yoshiyuki; Kanazawa, Hidenori; Sakamoto, Choitsu; Maruyama, Hitoshi; Yokosuka, Osamu; Mochida, Satoshi; Uemura, Masahito; Fukui, Hiroshi; Sumino, Yasukiyo; Matsuzaki, Yasushi; Masaki, Naohiko; Kokubu, Shigehiro; Okita, Kiwamu // Journal of Gastroenterology;Mar2012, Vol. 47 Issue 3, p313 

    Background: Treatment with terlipressin and albumin has been reported recently to be effective in improving renal function in the treatment of cirrhotic patients with hepatorenal syndrome (HRS). The aim of this prospective, multicenter study was to investigate the efficacy and safety of...

  • Medical management of hepatorenal syndrome. Davenport, Andrew; Ahmad, Jawad; Al-Khafaji, Ali; Kellum, John A.; Genyk, Yuri S.; Nadim, Mitra K. // Nephrology Dialysis Transplantation;Jan2012, Vol. 27 Issue 1, p34 

    Hepatorenal syndrome (HRS) is defined as the occurrence of renal dysfunction in a patient with end-stage liver cirrhosis in the absence of another identifiable cause of renal failure. The prognosis of HRS remains poor, with a median survival without liver transplantation of <6 months. However,...

  • Hepatorenal Syndrome: Outcome of Response to Therapy and Predictors of Survival. Heidemann, Jan; Bartels, Christoph; Berssenbrügge, Christoph; Schmidt, Hartmut; Meister, Tobias // Gastroenterology Research & Practice;4/23/2015, Vol. 2015, p1 

    Aim. Treatment of hepatorenal syndrome (HRS) in patients with liver cirrhosis is still challenging and characterized by a very high mortality. This study aimed to delineate treatment patterns and clinical outcomes of patients with HRS intravenously treated with terlipressin. Methods. In this...

  • Hepatorenales Syndrom. Huschak, G.; Kaisers, U.X.; Laudi, S. // Anaesthesist;Jul2013, Vol. 62 Issue 7, p571 

    Hepatorenal syndrome (HRS) is a unique form of acute renal failure occurring in patients with advanced cirrhosis or acute liver failure. In patients with ascites the incidence of HRS is 8 % and in end-stage liver disease 75 % of patients suffer from HRS. Vasodilation of splanchnic arteries with...

  • Renal failure in chronic liver disease and the hepatorenal syndrome. Srivastava, Brijesh; Alexander, Graeme J. M. // British Journal of Hospital Medicine (17508460);Sep2011, Vol. 72 Issue 9, p497 

    The article focuses on the aetiology and treatment of renal failure in chronic liver disease or liver cirrhosis, and explains the hepatorenal syndrome. It offers information on the circulatory disturbances in cirrhosis, and explores the investigations required in acute kidney injury. The article...

  • Organ tolerance following cadaveric liver transplantation for chronic graft-versus-host disease after allogeneic bone marrow transplantation. Urban, Ch.; Deutschmann, A.; Kerbl, R.; H., Lackner; Schwinger, W.; Konigsrainer, A.; Margreiter, R. // Bone Marrow Transplantation;10/15/2002, Vol. 30 Issue 8, p535 

    Presents a study that examined the effect of orthotopic liver transplantation after the development of cirrhosis of the liver. Details on the dysfunction of the liver; Causes of liver failure; Information on haematolymphopoietic chimerism.

  • Serum macrophage inflammatory protein 3α levels predict the severity of HBV-related acute-on-chronic liver failure. Jiaojiao Xin; Wenchao Ding; Shaorui Hao; Xin Chen; Jianing Zhang; Longyan Jiang; Qian Zhou; Dongyan Shi; Liyuan Zhang; Xiaowei Xu; Hongcui Cao; Lanjuan Li; Jun Li // Gut;Feb2016, Vol. 65 Issue 2, p355 

    A letter to the editor is presented in response to the article "Acute Kidney Injury and Acute-on-Chronic Liver Failure Classifications in Prognosis Assessment of Patients With Acute Decompensation of Cirrhosis," by P. Angeli et al published in a 2015 issue.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics